Cypress Bio Bags a Double

In the latest clinical trial, patients received one of two dosage strengths of milnacipran or a placebo. In measurements of pain, the study found that both 100 milligram and 200 milligram doses achieved statistically significant benefits compared with the placebo.

There were high drop-out rates for each group -- 35% for the high dose, 34% for the low dose and 28% for the placebo. The most common side effects that caused milnacipran patients to quit the test were nausea, palpitations, depression and headaches. Each side effect occurred in less than 5% of patients.

Forest and Cypress say milnacipran is sold in 32 foreign markets as a treatment for depression and has been available for seven years.

>To order reprints of this article, click here: Reprints